Nowadays, glioma molecular characteristics, such as the status of isocitrate dehydrogenase (IDH) mutation, methylation of O6-methylguanine-DNA methyltransferase (MGMT), and 1p/19q codeletion status, complement traditional therapy, and tumor-treating fields (TTFs) have been identified as important indicators for glioma classification and outcome prediction (1, 3). This evidence concerns the gene MGMT and glioma.